103,418 Shares of Edwards Lifesciences Corporation $EW Bought by Rakuten Investment Management Inc.

Rakuten Investment Management Inc. acquired a new position in Edwards Lifesciences Corporation (NYSE:EW) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 103,418 shares of the medical research company’s stock, valued at approximately $9,109,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in EW. Pin Oak Investment Advisors Inc. bought a new position in shares of Edwards Lifesciences during the 2nd quarter worth approximately $26,000. TrinityBridge Ltd purchased a new position in shares of Edwards Lifesciences in the 2nd quarter worth approximately $27,000. GK Wealth Management LLC purchased a new position in shares of Edwards Lifesciences in the 3rd quarter worth approximately $26,000. RMG Wealth Management LLC bought a new position in shares of Edwards Lifesciences in the first quarter valued at approximately $26,000. Finally, Compass Financial Management LLC bought a new position in shares of Edwards Lifesciences in the second quarter valued at approximately $32,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 544 shares of the firm’s stock in a transaction on Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the completion of the sale, the senior vice president directly owned 14,868 shares of the company’s stock, valued at $1,353,880.08. This trade represents a 3.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP Annette Brüls sold 2,644 shares of the business’s stock in a transaction on Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the sale, the vice president owned 17,984 shares in the company, valued at approximately $1,618,200.32. The trade was a 12.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 5,045 shares of company stock valued at $451,596. Company insiders own 0.31% of the company’s stock.

Edwards Lifesciences News Summary

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Edwards beat Q3 estimates, reporting adjusted EPS of $0.80 versus $0.74 expected and revenue of $1.72 billion, up about 11% year over year. It raised its full-year sales outlook and set adjusted EPS guidance of $2.97–$3.05. TAVR sales grew 8.8%, while transcatheter mitral and tricuspid therapies (TMTT) grew 45.6%, supporting the growth outlook. Q3 earnings and outlook
• Positive Sentiment: New PROGRESS Trial data found TAVR performed better than active surveillance for at-risk patients with moderate aortic stenosis, including fewer combined death or heart-failure events and better quality-of-life measures. The findings could support broader future use, though they do not by themselves establish a change in treatment or reimbursement. PROGRESS Trial data
• Positive Sentiment: Analysts responded favorably to the results: UBS raised its target to $118 and JPMorgan to $120, while other firms also increased targets and several upgraded the shares. The revisions signal improved expectations, but are analyst opinions rather than guaranteed returns. UBS price-target increase JPMorgan price-target increase
• Negative Sentiment: Edwards’ CEO acknowledged that more competition is coming in TAVR, a potential challenge to market share and growth. CEO comments on TAVR competition

Wall Street Analyst Weigh In

A number of brokerages recently commented on EW. Leerink Partners increased their price target on Edwards Lifesciences from $101.00 to $112.00 and gave the company an “outperform” rating in a research report on Thursday. UBS Group boosted their price objective on Edwards Lifesciences from $110.00 to $118.00 and gave the stock a “buy” rating in a research report on Thursday. BTIG Research upped their price objective on Edwards Lifesciences from $110.00 to $115.00 and gave the company a “buy” rating in a research note on Thursday. Argus upped their price objective on Edwards Lifesciences from $105.00 to $115.00 and gave the company a “buy” rating in a research note on Friday, August 21st. Finally, Wells Fargo & Company reaffirmed an “overweight” rating and set a $113.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research report on Thursday. Twenty-three investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $108.88.

Edwards Lifesciences Stock Up 1.3%

EW opened at $100.70 on Friday. Edwards Lifesciences Corporation has a twelve month low of $74.66 and a twelve month high of $104.17. The company’s 50-day moving average price is $88.68 and its two-hundred day moving average price is $85.69. The stock has a market cap of $57.99 billion, a price-to-earnings ratio of 56.90, a PEG ratio of 2.60 and a beta of 0.85. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Wednesday, November 4th. The medical research company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.06. Edwards Lifesciences had a net margin of 15.30% and a return on equity of 16.25%. The company had revenue of $1.72 billion during the quarter, compared to analyst estimates of $1.68 billion. During the same quarter last year, the business posted $0.67 EPS. Edwards Lifesciences’s quarterly revenue was up 10.5% compared to the same quarter last year. As a group, equities analysts expect that Edwards Lifesciences Corporation will post 3.00 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.